ZM-241,385
| ZM-241,385 | |
|---|---|
 | |
| IUPAC name 4-(2-(7-amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-ylamino)ethyl)phenol | |
| Identifiers | |
| CAS number | 139180-30-6  |
| PubChem | 176407 |
| ChemSpider | 153646  |
| ChEMBL | CHEMBL1628689 |
| IUPHAR ligand | 405 |
| Jmol-3D images | Image 1 |
| |
| |
| Properties | |
| Molecular formula | C16H15N7O2 |
| Molar mass | 337.34 g mol−1 |
| (verify) (what is: /?) Except where noted otherwise, data are given for materials in their standard state (at 25 °C (77 °F), 100 kPa) | |
| Infobox references | |
ZM-241,385 is a high affinity antagonist ligand selective for the adenosine A2A receptor.[1]
In animal models, ZM-241,385 has been shown to protect against beta amyloid neurotoxicity and therefore may be useful as a treatment for Alzheimer's disease.[2] ZM-241,385 has also been shown to enhance L-DOPA derived dopamine release and therefore may be useful in the treatment of Parkinson's disease.[3]
References
- ↑ Palmer TM, Poucher SM, Jacobson KA, Stiles GL (December 1995). "125I-4-(2-(7-amino-2-(2-furyl)(1,2,4)triazolo(2,3-a)(1,3,5) triazin-5-yl-amino)ethyl)phenol, a high affinity antagonist radioligand selective for the A2a adenosine receptor". Molecular Pharmacology 48 (6): 970–4. PMC 3479638. PMID 8848012.
- ↑ Dall'Igna OP, Porciúncula LO, Souza DO, Cunha RA, Lara DR, Dall'lgna OP (April 2003). "Neuroprotection by caffeine and adenosine A2A receptor blockade of beta-amyloid neurotoxicity". British Journal of Pharmacology 138 (7): 1207–9. doi:10.1038/sj.bjp.0705185. PMC 1573785. PMID 12711619.
- ↑ Gołembiowska K, Dziubina A (September 2004). "Striatal adenosine A(2A) receptor blockade increases extracellular dopamine release following l-DOPA administration in intact and dopamine-denervated rats". Neuropharmacology 47 (3): 414–26. doi:10.1016/j.neuropharm.2004.04.018. PMID 15275831.
External links
ZM 241385 at the US National Library of Medicine Medical Subject Headings (MeSH)
| ||||||||||||||||||||||